We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+38.67%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$144M
AUM Growth
+$17.4M
Cap. Flow
-$19.7M
Cap. Flow %
-13.73%
Top 10 Hldgs %
45.16%
Holding
104
New
9
Increased
14
Reduced
21
Closed
29

Top Buys

Rank Stock Value
1
TNDM icon
Tandem Diabetes Care
TNDM
+$3M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.63M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$2.32M
4
ONC
BeOne Medicines Ltd
ONC
+$2.04M
5
ARDX icon
Ardelyx
ARDX
+$1.98M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$4.73M
2
RIGL icon
Rigel Pharmaceuticals
RIGL
+$4.32M
3
NVAX icon
Novavax
NVAX
+$4M
4
DERM
Dermira, Inc.
DERM
+$3.05M
5
NXTM
NxStage Medical Inc.
NXTM
+$2.75M

Sector Composition

Rank Sector Weight
1 Healthcare 79.26%
2 Miscellaneous 20.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTAE
1
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$15M 10.43%
715,988
+55,800
+8% +$643K
CYNA
2
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$9.26M 6.45%
230,201
+7,842
+4% +$194K
ATRC icon
3
AtriCure
ATRC
$2.47B
$8.37M 5.83%
528,946
+15,000
+3% +$231K
NXTM
4
DELISTED
NxStage Medical Inc.
NXTM
$5.96M 4.15%
238,509
-118,000
-33% -$2.75M
TNDM icon
5
Tandem Diabetes Care
TNDM
$1.49B
$5.55M 3.86%
72,429
+41,153
+132% +$3M
ALDR
6
DELISTED
Alder Biopharmaceuticals
ALDR
$5.42M 3.77%
165,313
– –
LKFT
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$4.27M 2.98%
66,068
+2,500
+4% +$141K
XENE icon
8
Xenon Pharmaceuticals
XENE
$5.81B
$4.16M 2.9%
514,091
+300,000
+140% +$2.32M
AERI
9
DELISTED
Aerie Pharmaceuticals
AERI
$3.47M 2.41%
91,869
-69,000
-43% -$1.52M
LOXO
10
DELISTED
Loxo Oncology, Inc
LOXO
$3.41M 2.37%
130,222
+28,256
+28% +$739K
DERM
11
DELISTED
Dermira, Inc.
DERM
$3.34M 2.33%
98,800
-94,842
-49% -$3.05M
NBIX icon
12
Neurocrine Biosciences
NBIX
$15.7B
$3.24M 2.26%
64,008
-11,495
-15% -$572K
PODD icon
13
Insulet
PODD
$10.1B
$3.01M 2.1%
73,484
-18,680
-20% -$739K
TSRO
14
DELISTED
TESARO, Inc.
TSRO
$2.96M 2.06%
29,500
-500
-2% -$46.7K
ARDX icon
15
Ardelyx
ARDX
$984M
$2.83M 1.97%
219,095
+189,095
+630% +$1.98M
ONC
16
BeOne Medicines Ltd
ONC
$41.5B
$2.78M 1.93%
90,142
+70,142
+351% +$2.04M
PTGX icon
17
Protagonist Therapeutics
PTGX
$9.34B
$2.62M 1.82%
+123,804
New +$1.69M
FOMX
18
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.58M 1.79%
278,067
+85,500
+44% +$715K
AGTC
19
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.35M 1.64%
240,298
+73,106
+44% +$986K
RCKT icon
20
Rocket Pharmaceuticals
RCKT
$424M
$2.25M 1.57%
+59,309
New +$1.87M
SYRE icon
21
Spyre Therapeutics
SYRE
$7.97B
$2.25M 1.56%
14,016
– –
TVRD
22
Tvardi Therapeutics
TVRD
$24.3M
$2.23M 1.55%
7,418
– –
ISEE
23
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.15M 1.5%
+46,600
New +$2.63M
RDUS
24
DELISTED
Radius Health, Inc.
RDUS
$1.99M 1.39%
36,854
-746
-2% -$37.9K
IMMU
25
DELISTED
Immunomedics Inc
IMMU
$1.84M 1.28%
566,796
-248,204
-30% -$694K
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, DAFNA Capital Management held 104 positions worth $144M, up 14% from $126M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

DAFNA Capital Management withdrew a net $19.7M in Q3 2016, closing 29 positions and reducing 21 holdings. Its most notable exit was AbbVie, an estimated $4.73M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 85% a quarter earlier, followed by Miscellaneous.

Against the trend, DAFNA Capital Management opened a new position in IVERIC bio, Inc. Common Stock worth $2.15M.

  • DAFNA Capital Management's largest Q3 2016 buy was IVERIC bio, Inc. Common Stock: 46,600 shares worth $2.15M.
  • DAFNA Capital Management added most to Tandem Diabetes Care in Q3 2016, an estimated $3M increase.
  • DAFNA Capital Management's biggest Q3 2016 reduction was Rigel Pharmaceuticals, cutting an estimated $4.32M.
  • DAFNA Capital Management fully exited AbbVie in Q3 2016, selling an estimated $4.73M.
  • DAFNA Capital Management's ten largest holdings make up 45% of its $144M portfolio in Q3 2016.
  • DAFNA Capital Management opened 9 new positions and closed 29 in Q3 2016.
  • DAFNA Capital Management's portfolio value rose 14% quarter-over-quarter to $144M.

Based on DAFNA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.